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Abstract
 
Coreceptors CD28 and cytotoxic T lymphocyte antigen (CTLA)-4 have opposing effects on
TcR/CD3 activation of T cells. While CD28 enhances and CTLA-4 inhibits activation, the
underlying molecular basis of these effects has yet to be established. In this context, ganglioside
and cholesterol enriched membrane microdomains (rafts, GEMs) serve as centers of signaling in
T cells. Although CD28 can promote TcR/raft colocalization, evidence is lacking on whether
the surface expression of membrane rafts can be targeted by CTLA-4 in its modulation of T
cell responses. In this study, we demonstrate that both CD28 and CTLA-4 profoundly alter the
surface expression of membrane rafts during T cell activation. While CD28 increased expres-
sion and the number of peripheral T cells induced to express surface rafts in response to TcR li-
gation, CTLA-4 potently inhibited both TcR and TcR 
 
 
 
 CD28 induced raft expression on
the surface of T cells. Consistent with this, CD28 increased the presence of the linker of acti-
vated T cells (LAT) in purified membrane rafts, while CTLA-4 coligation effectively blocked
this increase. Further, the reversal of the CTLA-4 block with CD3/CD28 ligation was accom-
panied by an increase in surface raft expression and associated LAT. Our observations demon-
strate for the first time that CTLA-4 targets the release of rafts to the surface of T cells, and pro-
vides a mechanism for the opposing effects of CD28 and CTLA-4 on costimulation.
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Introduction
 
T cell activation is mediated by the antigen-receptor com-
plex (TcR
 
 
 
/CD3) and coreceptors CD28, inducible co-
stimulator (ICOS), and cytotoxic T lymphocyte antigen
(CTLA)-4 (CD152) (1, 2). CD28 and CTLA-4 have op-
posing effects with the coreceptors providing positive and
negative signals, respectively (3, 4). Despite their impor-
tance, the underlying mechanisms responsible for these op-
posing effects are unclear (5). CD28 has been reported to
bind to phosphatidylinositol 3-kinase (PI3-K), adaptors
Grb-2/GADS, and the phosphatase PP2A (6–11), while
CTLA-4 binds to PI3-K and phosphatases PP2A and SHP-2
(11–14). Debate concerns the relative roles of these ele-
ments in CD28 and CTLA-4 function (8, 11, 15, 16).
Glycosphingolipid/cholesterol enriched microdomains
(GEMs, Rafts, detergent-insoluble glycolipid-enriched do-
mains [DIGs], detergent-resistant membranes [DRMs]) on
the surface of cells act as platforms that compartmentalize
key components involved in signaling (17, 18). Rafts are
enriched with GPI-linked proteins, palmitoylated trans-
membrane adaptors such as LAT (linker for activation of T
cells), and myristoylated kinases such as p56
 
lck
 
 and p59
 
fyn
 
(19–22). While the integrity of rafts is required for efficient
T cell activation (22), the engagement of the TcR can pro-
mote its movement into rafts (23). In this context, CD28
coengagement can induce raft expression under conditions
where TcR ligation failed to achieve this event, and has
been reported to promote the colocalization of rafts with
TcR complexes (24). In resting T cells, rafts as identified by
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GM1 staining have been found localized in intracellular
compartments and are released to the cell surface with re-
ceptor ligation (25). In this context, memory and effector
T cells have been reported to express higher levels of rafts
than resting T cells (25). In addition to kinases, rafts are en-
riched with other signaling proteins. In this context, a fam-
ily of immune cell specific adaptor proteins have been
identified in recent years (26–28). Of particular note is the
transmembrane adaptor protein LAT which is preferen-
tially associated with rafts due to its palmitoylation (29, 30).
Although CD28 promotes raft expression, there has been
a lack of evidence on whether alterations in the formation of
surface rafts can explain the opposing effects of CD28 and
CTLA-4 on the costimulation of T cells. In this study, we
report that while CD28 greatly increased the number of
GM1 negative peripheral T cells that become positive as a
result of TcR ligation, CTLA-4 profoundly inhibited the
expression of surface rafts. This was confirmed biochemi-
cally where CD28 augmented the detection of the adaptor
LAT in purified rafts, while CTLA-4 coligation blocked this
increase at the level of resting T cells. Further, the reversal
of the CTLA-4 block by CD3/CD28 ligation was accom-
panied by an increase in surface raft expression and associ-
ated LAT. Our observations demonstrate for the first time
that CTLA-4 targets raft expression on the surface of T cells,
a finding that provides an explanation for the opposing ef-
fects of CD28 and CTLA-4 on the costimulation of T cells.
 
Materials and Methods
 
Cells, Reagents, and Antibodies.
 
Peripheral blood cells were
isolated from the buffy coat by lymphocyte separation medium
(Ficoll-Paque) density gradient centrifugation. The nonadherent
cells were cultured in RPMI 1640 supplemented with 10% (vol/
vol) FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 2
mM L-glutamine. Anti–CTLA-4 mAb was purchased from Im-
munotech. Avidin-Texas Red, mouse IgG2a (specific for 2,4,6-
trinitropenol; TNP), biotinylated anti–CTLA-4 and FITC-labeled
CD25 were bought from BD PharMingen. Anti-OKT3 and anti-
CD28 (9.3) were obtained from American Type Culture Collec-
tion and Bristol-Myers Squibb, respectively. Saponin and Cholera
toxin (Ctx, B-subunit) were obtained from Sigma-Aldrich. Poly-
urethane-coated tosyl-activated Dynabeads were purchased from
Dynal. Fluoromount-G was bought from Southern Biotechnology
Associates, Inc. Anti-LAT and anti-lck antibodies were purchased
from Upstate Biotechnology. Anti-CD3, anti-CD28, anti–CTLA-4,
and anti-TNP mAbs were attached to Dynabeads following the
manufacturer’s instructions. The bead to cell ratio was 1:1. The ra-
tio of anti-CD28 to anti–CTLA-4 was 1:5. Anti-TNP (IgG2a)
was used as an isotype specific control for CTLA-4.
 
Ctx and CTLA-4 Staining of Naive and Activated Peripheral T
Cells.
 
Purified naive T cells were stimulated with antibody-
coated beads (anti-CD3/TNP; anti-CD3/CTLA-4; anti-CD3/
CD28/TNP, and anti-CD3/CD28/CTLA-4) for various periods
of time at 37
 
 
 
C. Cells were stained with FITC-labeled Ctx
B-subunit, fixed with 1% paraformaldehyde, and analyzed by flow
cytometry (Cytometer XL; Beckman Coulter). For immunofluo-
rescence microscopy studies, purified naive T cells were activated
with plate-bound anti-CD3 and anti-CD28 antibodies (5 
 
 
 
g/ml
of each) for 48 h to induce CTLA-4 expression. Staining with
FITC-labeled Ctx was performed under permeabilizing and non-
permeabilizing conditions. In the first case, cells were fixed with
2% paraformaldehyde for 20 min, washed, and permeabilized
with PBS containing 0.03% saponin. After 30 min incubation
with FITC-labeled Ctx and biotinylated CTLA-4 mAb at 4
 
 
 
C in
PBS containing 0.3% saponin and 2% BSA, cells were washed
and incubated with Avidin-Texas Red (1 
 
 
 
g/ml) for further 30
min at 4
 
 
 
C. Before mounting with Fluoromount G, cells were
incubated for 5 min with Hoechst (1 
 
 
 
g/ml) to stain nuclei.
Under nonpermeabilizing conditions, cells were first stained
with FITC-labeled Ctx, then washed, fixed, and permeabilized as
described above. Cells were then incubated with biotinylated
CTLA-4 mAb and Avidin-Texas Red, mounted, and visualized
by microscopy.
 
Proliferation Assays.
 
Purified naive T cells were cultured in
96-well plates at a density of 2 
 
 
 
 10
 
5
 
 cells and activated with
anti-CD3/CD28/IgG2a and anti-CD3/CD28/CTLA-4 coated
beads for 48 h. After this period of time, cells were washed, and
beads were removed by using a magnet. Cells were then restimu-
lated with anti-CD3/CD28 coated beads for further 48 h. To as-
say proliferation, cells were pulsed with 1 
 
 
 
Ci of [
 
3
 
H]thymidine
for the last 18 h of the indicated periods of time. In parallel, cells
were stained for surface GM1 expression as described above.
 
GEM Isolation.
 
The GEM fractions were purified as a Triton
X-100 insoluble fraction at the 5/35% interface as described (31).
Anti-CD3/CD28 and anti-CD3/CD28/CTLA-4 stimulated T
cells (19 h) were washed and resuspended with 1 ml of ice-cold
MBS (25 mM MES, 150 mM NaCl, pH 6.5), 0.5% Triton X-100,
1 mM Na
 
3
 
VO
 
4
 
, 2 mM EDTA, 1 mM PMSF, and 1 
 
 
 
g/ml apro-
tinin. After a 30-min incubation on ice, the lysates were homog-
enized with 10 strokes of a loose-fitting Dounce homogenizer,
gently mixed with an equal volume of 85% sucrose(wt/vol) in
MBS, and overlaid with 6.5 ml of 35% sucrose and 3.5 ml of 5%
sucrose in MBS with 1 mM Na
 
3
 
VO
 
4
 
 and spun for 16–19 h at
200,000 
 
g
 
 at 4
 
 
 
C in a Beckman SW40Ti. 1 ml fractions were har-
vested from the top of the gradient. The GEM and TSF (triton
soluble fraction) fractions were obtained in fractions 3–5 and 10–
12, respectively.
 
Western Blotting.
 
Equal amounts of cell lysates (40 
 
 
 
 10
 
6
 
cells) from the GEM and TSF fractions was separated on a 12%
SDS-PAGE and transferred to nitrocellulose for immunoblotting.
Ponceau S staining of the transferred proteins served as a control
for loading. The membranes were then blocked with 5% milk in
TBS (10 mM Tris-HCL, pH 7.6, 150 mM NaCl) and incubated
with the indicated antibodies. Bound antibody was revealed with
HRP-conjugated rabbit anti–mouse or donkey anti–rabbit anti-
bodies using enhanced chemiluminescence (ECL; Amersham
Pharmacia Biotech).
 
Results and Discussion
 
Given the profound opposing effects of CD28 and
CTLA-4 on T cell activation (1–3) and the importance of
ganglioside/cholesterol enriched rafts in signaling (17, 18),
we investigated whether raft formation on the cell surface is
targeted by the coreceptors. GM1 serves as a marker for the
presence of membrane rafts on the surface of mammalian
cells (18). The B-subunit of Ctx conjugated to FITC binds
to GM1 and as such can detect surface expression of the
ganglioside (32). Peripheral T cells were cross-linked with
anti-CD3 with or without anti-CD28 or anti–CTLA-4,
and assessed for GM1 expression by Ctx-FITC staining 
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(Fig. 1 A). Anti-CD3 ligation induced raft surface expres-
sion where the percentage of GM1-positive cells increased
from 7–10 on resting cells to 35–40% of the population
over a period of 96 h on activated cells. Significantly, coli-
gation with CD28 enhanced the percentage of GM1 posi-
tive cells to 70–80% of the population (i.e., an increase of
two- to threefold that was observed in six experiments; Fig.
1 A). CD28 coligation also increased the mean intensity of
fluorescence (MIF) on positively gated cells (i.e., 48 h:
anti-CD3: 12.1, anti-CD3/CD28: 13.7; 72 h: anti-CD3:
Figure 1. CD28 and CTLA-4
regulate the formation of membrane
rafts on the surface of T cells. (A)
Resting human peripheral T cells
were (2   105) were stimulated
with the following mAbs coated to
Dynabeads: anti-CD3 (rectangle),
anti-CD3/CTLA-4 (circle), anti-
CD3/CD28 (triangle), and anti-
CD3/CD28/CTLA-4 (crossed
square) for 0, 24, 48, 72, and 96 h.
Nonstimulated cells (square) served
as a negative control. After the indi-
cated time, cells were washed,
stained with Ctx-FITC, fixed, and analyzed for GM1-
positive cells (percentage). (B) Resting human cells stimu-
lated with anti-CD3 (gray bars), anti-CD3/CTLA-4
(striped bars), anti-CD3/CD28 (hatched bars), and anti-
CD3/CD28/CTLA-4 (black bars) coated beads for 24
and 48 h were pulsed with [3H]thymidine for the last 18 h
at the indicated periods of time. Cells cultured in media
alone served as a negative control (dotted bars). (C) Rest-
ing human peripheral T cells were stimulated with anti-
CD3/CD28 (triangle) and anti-CD3/CD28/CTLA-4
(circle) coated beads for 0, 24, 48, and 72 h. Nonstimu-
lated cells served as a negative control (square). After the
indicated time, cells were washed and stained with anti
CD25-FITC and Ctx-FITC, fixed, and analyzed for
CD25 and Ctx surface expression by FACS®. (D) Immu-
nofluorescence visualization of GM1 and CTLA-4 ex-
pression in resting and activated peripheral T cells. Rest-
ing lymphocytes were first permeabilized and then stained
with Hoechst and FITC-labeled Ctx (a) or FITC-labeled
Ctx and biotinylated CTLA-4/anti–IgG2a- Avidin-Texas
Red (a ). Panel b: nonpermeabilized resting lymphocytes
were stained with Hoechst and FITC-labeled Ctx (b), or
stained only with FITC-labeled Ctx followed by fixation,
permeabilization, and staining with biotinylated CTLA-4/
anti–IgG2a-Avidin-Texas Red (b ). Panel c: to activate
peripheral blood lymphocytes, cells were incubated with
plate-bound anti-CD3 plus anti-CD28 mAbs (5  g/ml of
each). After 48 h, cells were first stained with Hoechst and
FITC-labeled Ctx (c), and then additionally fixed, perme-
abilized, and stained with biotinylated CTLA-4/anti-
IgG2a-Avidin-Texas Red (c ). 
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15.6, anti-CD3/CD28: 17.4). However, the CD28 effect
was more pronounced on the increase in numbers of naive
peripheral T cells to express surface rafts as a result of TcR
ligation (i.e., GM1-positive cells at 48 h: anti-CD3 versus
anti-CD3/CD28: 40 to 60%; MIF: anti-CD3 versus anti-
CD3/CD28: 12.1 [61%] to 13.7 [69%]). Anti-CD28 alone
had not obvious effect on raft formation. As a control, up-
regulation in the presence of membrane rafts was accompa-
nied by enhanced T cell proliferation (Fig. 1 B). These data
show that CD28 can cooperate with the TcR in the poten-
tiation of raft expression, especially by enhancing the per-
centage of peripheral T cells that are induced to express
rafts in response to TcR ligation.
Given the opposing negative effect of CTLA-4 on T
cell activation (4, 5), we next assessed whether CTLA-4
coligation could alter the surface expression of rafts. Coli-
gation of CTLA-4 with either TcR, or the combination
of TcR and CD28 potently inhibited GM1 expression
(Fig. 1 A). On average, CTLA-4 inhibited the percentage
of GM1-positive cells by 70–90% so that the level of ex-
pression at 48–96 h exceeded that of the resting popula-
tion by only 5–10%. CTLA-4 also inhibited the expression
level on cells that had been induced to express GM1 as a
result of anti-CD3 or anti-CD3/CD28 ligation (i.e., MIF
of positively gated cells), albeit to a much lesser extent
(i.e., MFI: 48 h: anti-CD3 versus anti-CD3/CTLA-4:
12.1 [61%] to 11.0 [55%]; anti-CD3/CD28 versus anti-
CD3/CD28/CTLA-4: 13.6 [69%] to 11.9 [60%]). Inhibi-
tion of GM1 expression correlated with the anti–CTLA-4
blockage of proliferation (Fig. 1 B), and CD25 expression
(Fig. 1 C). Our findings therefore show that CD28 and
CTLA-4 have striking opposite effects on the surface ex-
pression of rafts in a manner that mimic their effects on T
cell proliferation. To our knowledge, this is the first report
to document a regulatory effect of CTLA-4 on the expres-
sion of membrane rafts on the surface of T cells.
Membrane rafts are released from intracellular compart-
ments to the plasma membrane due to receptor ligation
(18, 25, 33). Immunofluorescence microscopy confirmed
that anti-CD3/CD28 induced the release of GM1 from the
cytoplasm to surface of resting human T cells (Fig. 1 D).
Peripheral T cells were either permeabilized with saponin
to visualize both intracellular/surface staining (Fig. 1 D, a
and c), or were left in a nonpermeabilized state to visualize
surface staining (Fig. 1 D, b). Hoechst staining was used to
visualize the nucleus of permeabilized and nonpermeabi-
lized cells (Fig. 1 D, a–c). Ctx staining of permeabilized
resting T cells showed extensive intracellular staining for
GM1 (Fig. 1 D, a
 
 
 
), while the majority of nonpermeabi-
lized resting cells showed no immunofluorescence staining
(Fig. 1 D, b
 
 
 
). By contrast, anti-CD3/CD28 activation
showed extensive surface expression of GM1 (Fig. 1 D, c
and c
 
 
 
). As expected from the detection of staining by
FACS
 
®
 
, CTLA-4 coligation reduced the number of cells
that stained positively for surface GM1 (data not shown;
same as in Fig. 1 D, b
 
 
 
). An additional observation was that
amongst the anti-CD3/CD28 activated T cells, individual
cells that stained strongly for CTLA-4 failed to express
GM1, while other cells that expressed high levels of
CTLA-4 tended to be negative for GM1 (Fig. 1 D, c
 
 
 
).
A key signaling protein in membrane rafts is the palmi-
toylated transmembrane adaptor protein LAT (29, 30). To
obtain a biochemical correlate to raft formation, we next
examined the ability of anti–CTLA-4 to inhibit raft forma-
tion by examining the presence of LAT in purified mem-
brane rafts or GEMs. A Triton X-100 insoluble fraction
(i.e., raft fractions) was isolated at the 5/35% interface of
discontinuous sucrose gradient (31, 34). Of the 12 collected
fractions, fractions 3–5 correspond to the GEM fraction,
while fractions 10–12 correspond to the Triton-soluble
fraction (Fig. 2 A). Subsequent blotting with GPI-linked
CD48 showed an exclusive localization to the GEM frac-
tion (Fig. 2 A, top panel). Blotting with anti-LAT showed
its presence in both the GEM and non-GEM fractions (Fig.
2 A, middle panel), as reported previously (21). Blotting
with anti-p56
 
lck
 
 showed that Lck segregated primarily to
the GEM fraction (Fig. 2 A, bottom panel). Our first ob-
servation was that anti-CD28 co-cross-linking resulted in
the presence of a larger band at the sucrose interface (i.e.,
two- to threefold larger than in anti-CD3 activated sam-
ples), while anti–CTLA-4 blocked this increase (data not
shown). Consistent with this, anti-CD3/CD28 stimulation
increased the amount of LAT protein from purified GEMs
when compared with untreated membranes (i.e., pooled
samples from fractions 3–5; Fig. 2 B, lanes 2 versus 1). Fur-
ther, coligation of CTLA-4 with TcR 
 
  
 
CD28 inhibited
the increase in the presence of LAT associated with the raft
fraction (Fig. 2 B, lanes 3 versus 2). Significantly, anti-
CTLA-4 blocked the TcR/CD28-mediated increase in
LAT expression by 50–70% as measured by densitometric
scanning (Fig. 2 B, right panel). An alteration in the pres-
ence of LAT in the non-raft fraction was not as easily ob-
served, presumably due to the relatively small amount of
LAT transferred to the raft fraction relative to the total
amount of protein (Fig. 2 B, bottom panel). Despite this,
the finding that the coreceptors altered the level of LAT in
the raft fraction was a consistent observation.
Given the above data, we next assessed whether the re-
versal of the CTLA-4 blockade by secondary stimulation
with anti-CD3/CD28 resulted in the restoration of raft
formation on the surface of cells (Fig. 3 A). Anti–CTLA-4
inhibited CD3/CD28-induced appearance of GM1 posi-
tive cells when assayed at 48 h (i.e., Fig. 3 A, b, c, and e).
Restimulation of these cells with anti-CD3/CD28 reversed
this inhibition with an increase in GM1 expression where
80–85% of the population stained positive for GM1 48 h
later (Fig. 3 A, d). The level of this increase in expression
was similar to that observed in primary anti-CD3/CD28
activated cells that had been restimulated with anti-CD3/
CD28 (i.e., 88% expression; Fig. 3 A, f). Restimulation of
cells with anti-CD3/CD28 caused a concordant recovery
of proliferation (Fig. 3 B). Further, as shown in Fig. 3 C,
the recovery of raft formation was also evident with an in-
crease in the detection of raft-associated LAT. Cells stimu-
lated with anti-CD3/CD28 (i.e., for 5 and 48 h) showed
increased amounts of LAT in the raft fraction when com- 
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pared with untreated cells (Fig. 3 C, lanes 1 versus 2 and 3).
Coligation with anti–CTLA-4 suppressed this increase in
LAT expression (Fig. 3 C, lane 4 versus 2). However, re-
stimulation with anti-CD3/CD28 reversed the CTLA-4–
mediated blockage by increasing the amount of LAT in the
rafts (Fig. 3 C, lane 5). As mentioned, this reversal of LAT
expression was mimicked by the ability of anti-CD3/
CD28 to reverse the blockage in proliferation (Fig. 3 B).
These findings further underlie the close relationship be-
tween CD28 and CTLA-4 modulation of proliferation and
the expression of membrane rafts on the surface of T cells.
In summary, our data demonstrating that CTLA-4 as
well as CD28 can regulate the expression of membrane rafts
on the surface of T cells provides a mechanism to account
for the opposing effects of these coreceptors on the T cell
response. CTLA-4 ligation potently blocked the induction
of raft surface expression caused by TcR ligation alone, or
in combination with CD28 (Fig. 3 D). Alterations in raft
surface expression therefore represent a novel target for
CTLA-4, and provide a mechanism by which this corecep-
 
tor can attenuate TcR signaling. Of particular note was the
potency with which CTLA-4 blocked both TcR and
TcR 
 
 
 
 CD28 induced raft expression, and the degree to which
the positive and negative effects of CD28 and CTLA-4 on
raft formation was closely paralleled effects on T cell activa-
tion. After anti–CTLA-4 coligation, the percentage of cells
expressing rafts was only slightly greater than for resting T
cells. Although CTLA-4 reduced the expression on TcR-
induced GM1-positive cells, a more profound effect was
observed on the enhanced numbers of cells to appear as a
result of CD28 costimulation. This is in keeping with the
fact that the primary function of CD28 was to increase the
number of cells that become positive as a result of TcR li-
gation. By preventing the intracellular release of these cru-
cial signaling platforms, CTLA-4 will prevent TcR-raft in-
teractions needed for efficient signaling. Indeed, the
reduction in overall raft expression was accompanied by the
reduction in the level of raft-associated LAT, a key integra-
tor of TcR signaling. This may account for the reported re-
duction in LAT phosphorylation upon CTLA-4 coligation
(13). Further, our findings show that this inhibitory effect
was not fixed, but rather readily reversed with anti-CD3/
CD28 coligation, an event that caused the reexpression of
GM1, raft-associated LAT, and proliferation (Fig. 3). Raft
microdomains serve as platforms that are enriched with key
signaling molecules for efficient TcR signaling. By modu-
lating raft expression and the percent of the surface area of
the plasma membrane that constitutes raft microdomains,
the two coreceptors would promote or prevent crucial in-
teractions between TcR, LAT, and other components
needed for signaling. These opposing effects on raft forma-
tion could account for the opposing effects of these core-
ceptors on the T cell response.
Our findings also provide a different perspective on the
enhancing effects of CD28 on raft expression. While Viola
and coworkers made the first important observation that
CD28 can induce GM1 surface expression on cells, they
failed to observe an effect of TcR
 
 
 
/CD3 itself (24). Our
findings show that anti-CD3 ligation can also induce raft
expression on the T cell surface, and that this antigen recep-
tor–mediated effect is potentiated by anti-CD28 ligation.
CD28 therefore does not provide a unique signal for the re-
lease of rafts to the cell surface that cannot also be provided
by the TcR. Second, our findings show that while CD28
can enhance GM1 expression on cells induced by TcR liga-
tion, its principal effect was to increase the recruitment of
new cells to express membrane rafts that would not nor-
mally do so with TcR ligation alone. By increasing the
number of cells with the appropriate microenvironment for
more efficient TcR signaling, CD28 would be expected to
increase the number of cells capable of responding to a
given antigen. Lastly, although Tuosto et al. (25) have pre-
viously shown increased expression levels of GM1 after
anti-CD3/CD28 stimulation, the issue of whether CD28
could potentiate the anti-CD3–mediated induction of GM1
was not assessed. Both of our studies confirm that GM1 is
released from intracellular stores in response to signals from
TcR (in our study) or TcR 
 
 
 
 CD28 (both studies). Our
Figure 2. Raft associated LAT is reduced by CTLA-4 coligation. (A)
Separation of GEMs and Triton X-100 soluble material by discontinuous
sucrose gradient. The GEM fraction were purified as a Triton X-100 insol-
uble fraction at the 5/35% interface as described (reference 31). Fractions 3–5
correspond to the GEM fraction, while fractions 10–12 correspond to the
Triton-soluble fraction. Equal amounts of cell lysates of fractions 1–12 were
loaded and immunoblotting was performed with anti-CD48 (top panel),
anti-LAT (middle panel), and anti-lck (bottom panel) antibodies. (B)
CTLA-4 coligation with anti-CD28/CD3 reduces the presence of LAT in
the GEM fraction. Left panel: equal amounts of cell lysates from GEM frac-
tions (3–5) and triton-soluble fractions (10–12) obtained from untreated T
cells (lane 1), or stimulated for 19 h with anti-CD3/CD28 (lane 2) and
anti-CD3/CD8/CTLA-4 (lane 3) were separated on a 12% SDS-PAGE
and immunoblotted with anti-LAT antibody. Right panel: histogram de-
piction of the levels of LAT protein as detected by densitometric reading. 
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findings are also in keeping with the observation that effec-
tor T cells with higher levels of raft expression than naive T
cells are less dependent on co-stimulation (29, 35). Given
that a function of CD28 is to promote raft expression, cells
with high levels of expression would be expected to be less
dependent on the function of the coreceptor.
Regulation of surface rafts may eventually be found to
represent a general mechanism by which costimulation by
other coreceptors such as ICOS amplify signaling. Further
studies will be needed to unravel the proximal biochemical
signals that connect coreceptors with the release of rafts
from intracellular stores.
Figure 3. CD28 reverses the CTLA-4 block in the formation of rafts as assessed by GM1 expression and levels of raft-associated LAT. (A) Purified naive
T cells were activated with anti-CD3/CD28/CTLA-4 or anti-CD3/CD28/TNP coated beads for 48 h (primary stimulation). After this period of time,
anti-CD3/CD28/CTLA-4 or anti-CD3/CD28/TNP activated cells were washed and stained with Ctx-FITC for surface GM1 expression, respectively (c
and e). Cells stained with goat anti–mouse FITC served as a negative control (a). Restimulation (secondary stimulation) was then performed by incubating
the cells with anti-CD3/CD28 coated beads for further 48 h, respectively (d and f). After this time, cells were washed, stained with Ctx-FITC and analyzed
for GM1 surface expression by FACS®. GM1 surface expression in resting PBLs is shown in panel b. (B) Proliferation was measured by pulsing the cells,
stimulated as described in panel A, with [3H]thymidine for the last 18 h. Control (dotted bars), anti-CD3/CD28 (1 ) followed by anti-CD3/CD28 (2 ) (light
gray bars), and anti-CD3/CD28/CTLA-4 (1 ) followed by anti-CD3/CD28 (2 ) (dark gray bars). (C) Equal amounts of cell lysates from GEM fractions (3–5)
obtained from untreated and stimulated cells were separated on a 12% PAGE-Gel and immunoblotted with anti-LAT antibody. Lane 1: untreated cells;
lanes 2 and 3: cells stimulated with anti-CD3/CD28 mAbs for 5 h (lane 2) and restimulated with anti-CD3/CD28 mAbs for 48 h (lane 3); lanes 4 and 5:
cells stimulated with anti-CD3/CD28/CTLA-4 mAb for 5 h (lane 4) and restimulated with anti-CD3/CD28 mAbs for 48 h (lane 5); lanes 6 and 7: cells
stimulated with anti-CD3/CD28/CTLA-4 mAbs for 10 h (lane 6) and 20 h (lane 7). (D) Model of CTLA-4 blockage of raft expression on the surface of T
cells. TcR can induce the appearance of rafts on the surface of T cells. CD28 enhances raft expression induced by TcR ligation, and especially can increase
the recruitment of cells to express membrane rafts that would not normally do so with TcR ligation alone. By contrast, CTLA-4 reduced the expression on
TcR-induced GM1-positive cells, and dramatically on the numbers of cells to express rafts as a result of CD28 costimulation. Both the level of GM1 expres-
sion and the presence of the adaptor protein LAT in rafts was altered in a manner consistent with the opposing effects on the coreceptors on T cell function. 
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